glp 1 agonist depression GLP-1 receptor agonists show promise in treating substance use disorders Doctors and patients across social

In the case of hepatic steatosis, insulin signaling pathways are largely deficient

Conclusions/interpretation In individuals with NAFLD and type 2 diabetes, GLP-1RAs are associated with lower incidences of adverse CVEs and all-cause mortality compared with metformin or other second- and third-line glucose-lowering medications

Herein, we briefly describe therapeutic agents/compounds that enhance GLP-1 function

1 Role in Therapy Many studies and reviews have explored the role of GLP-1 RAs within diabetes management

4 In contrast, Eli Lillys upcoming oral GLP1 candidate, orforglipron, is a smallmolecule drug rather than a peptide, which could lessen the need for dosing requirements and offer greater convenience to users

Read more: To view or add a comment, sign in A new study presented at the European Society of Cardiology Congress 2025, powered by Truveta Data from more than 200,000 patients, found: Early discontinuation was linked to higher cardiovascular risks